Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 255-261

  Zhao, Ni ^a,b   Wilkerson, Matthew D ^a,d   Shah, Usman ^c   Yin, Xiaoying ^a   Wang, Anyou ^a   Hayward, Michele C ^a   Roberts, Patrick ^a   Lee, Carrie B ^a,d   Parsons, Alden M ^d   Thorne, Leigh B ^a,d   Haithcock, Benjamin E ^d   Grilley Olson, Juneko E ^a,d   Stinchcombe, Thomas E ^a,d   Funkhouser, William K ^a,d   Wong, Kwok Kin ^e   Sharpless, Norman E ^a,d   Hayes, D Neil ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c LEHIGH VALLEY HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain metastasis; KRAS; LKB1; NSCLC; Prognostic model

Indexed keywords

K RAS PROTEIN; PROTEIN KINASE LKB1; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FROZEN SECTION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; SMOKING; SURVIVAL TIME; BRAIN TUMOR; CANCER STAGING; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ODDS RATIO; ONCOGENE RAS; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; ROC CURVE;

EID: 84908398337     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.013     Document Type: Article

References (35)

1. Laskin J.J.S.A., Johnson D.H. Non-small cell lung cancer 2005, Saunders, Philadelphia, PA.
2. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
3. Ampil F., Caldito G., Milligan S., Mills G., Nanda A. The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role. Lung Cancer 2007, 57:60-65.
4. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011, 8:344-356.
5. Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007, 26:5911-5918.
6. Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
7. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391:184-187.
8. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002, 62:3659-3662.
9. Zhuang Z.G., Di G.H., Shen Z.Z., Ding J., Shao Z.M. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 2006, 4:843-849.
10. Tiainen M., Ylikorkala A., Makela T.P. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A 1999, 96:9248-9251.
11. Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol 2000, 49:187-195.
12. Wilkerson M.D., Yin X., Walter V., Zhao N., Cabanski C.R., Hayward M.C., et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS ONE 2012, 7:e36530.
13. Wilkerson M.D., Yin X., Hoadley K.A., Liu Y., Hayward M.C., Cabanski C.R., et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010, 16:4864-4875.
14. Ritchie M.E., Silver J., Oshlack A., Holmes M., Diyagama D., Holloway A., et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007, 23:2700-2707.
15. Aviel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8:30-38.
16. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010, 38:e164.
17. Bengtsson H., Ray A., Spellman P., Speed T.P. A single-sample method for normalizing and combining full-resolution copy numbers from multiple platforms, labs and analysis methods. Bioinformatics 2009, 25:861-867.
18. Shuster J.J. Median follow-up in clinical trials. J Clin Oncol 1991, 9:191-192.
19. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
20. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
21. Slotman B., Faivre-Finn C., Kramer G., Rankin E., Snee M., Hatton M., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672.
22. Stuschke M., Eberhardt W., Pottgen C., Stamatis G., Wilke H., Stuben G., et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999, 17:2700-2709.
23. Gore E.M., Bae K., Wong S.J., Sun A., Bonner J.A., Schild S.E., et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2010, 29:272-278.
24. William W.N., Kim J.S., Liu D.D., Solis L., Behrens C., Lee J.J., et al. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 2011, 23:78-85.
25. Nanjundan M., Byers L.A., Carey M.S., Siwak D.R., Raso M.G., Diao L., et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2014, 5:1894-1904.
26. Makowski L., Hayes D.N. Role of LKB1 in lung cancer development. Br J Cancer 2008, 99:683-688.
27. Launonen V. Mutations in the human LKB1/STK11 gene. Hum Mutat 2005, 26:291-297.
28. Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 1998, 58:1384-1386.
29. Esteller M., Avizienyte E., Corn P.G., Lothe R.A., Baylin S.B., Aaltonen L.A., et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 2000, 19:164-168.
30. Gill R.K., Yang S.H., Meerzaman D., Mechanic L.E., Bowman E.D., Jeon H.S., et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011, 30:3784-3791.
31. Liu W., Monahan K.B., Pfefferle A.D., Shimamura T., Sorrentino J., Chan K.T., et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012, 21:751-764.
32. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2014, 118:4502-4511.
33. Cox J.D., Yesner R.A. Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am Rev Respir Dis 1979, 120:1025-1029.
34. Figlin R.A., Piantadosi S., Feld R. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med 1988, 318:1300-1305.
35. Shaikh T.H. Oligonucleotide arrays for high-resolution analysis of copy number alteration in mental retardation/multiple congenital anomalies. Genet Med 2007, 9:617-625.